WRAP Retail Offer

EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £500,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"). Under the WRAP Retail Offer up to 4,166,667 new ordinary Shares (the "WRAP Retail Offer Shares") will be made available at a price of 12 pence per WRAP Retail Offer Share.

In addition to the WRAP Retail Offer, the Company has today approved the issue of 12,966,667 new ordinary shares of 1p each in the Company at a price of 12p per share (the "Subscription", "Subscription Shares") to raise £1.56 million. The Subscription completes a fund-raising round that has raised £5.7million, in aggregate, at 12p per share, following the Company's announcement on 4 February of a placing of shares to raise £4.01 million.

A separate announcement has been made regarding the placing of Subscription Shares (the "Placing Announcement") which sets out the reasons for the placing of Subscription Shares and the indicative use of funds. It is proposed that the net proceeds of the WRAP Retail Offer will also be used to support the acceleration of the development of products to help meet global demand from healthcare providers delivering personalised treatments, as indicated in the Placing Announcement.

Completion of the WRAP Retail Offer is conditional, inter alia, on any WRAP Retail Offer Shares and the Subscription Shares ("New Ordinary Shares") being admitted to trading the Access Segment of the Aquis Stock Exchange Growth Market. It is anticipated that an application will be made to the Aquis Exchange PLC for Admission for the New Ordinary Shares to be admitted to trading ("Admission"). It is currently anticipated that Admission will become effective, and that dealings in the Subscription Shares and WRAP Retail Offer Shares will commence on the Access Segment of the Aquis Stock Exchange Growth Market, at 8.00 a.m. on 11 March 2024.

WRAP Retail Offer

The Company values its retail shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom with the opportunity to participate in the WRAP Retail Offer.

Therefore, the Company is making the WRAP Retail Offer open to eligible investors in the United Kingdom, being existing shareholders of EDX Medical Group plc, following release of this announcement and through certain financial intermediaries. Existing shareholders should contact their broker or wealth manager to participate in the WRAP Retail Offer.

The WRAP Retail Offer is expected to close at 4.30 p.m. on 5 March 2024. Eligible shareholders should note that financial intermediaries may have earlier closing times. The result of the WRAP Retail Offer is expected to be announced by the Company on or around 6 March 2024.

There is no minimum subscription per investor under the WRAP Retail Offer. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.

It is a term of the WRAP Retail Offer that the total value of the WRAP Retail Offer Shares available for subscription at the issue price does not exceed €8 million.

No offering document, prospectus or admission document has been or will be prepared or submitted to be approved by the Financial Conduct Authority (or any other authority) in relation to the WRAP Retail Offer, and investors' commitments will be made solely on the basis of the information contained in this announcement and information that has been published by or on behalf of the Company prior to the date of this announcement by notification to a Regulatory Information Service in accordance with the Aquis Stock Exchange Access Rulebook, the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Market Abuse Regulation (EU Regulation No. 596/2014) as it forms part of the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018 (as amended).

Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7.00 a.m. on 28 February 2024.

The Company's LEI is 213800BZVJZTMCZ6DJ63.